| Recruiting | Vaccine- and Infection-derived Correlates of Protection for Cholera NCT06455852 | Massachusetts General Hospital | N/A |
| Recruiting | Testing a Scalable Model of the Cholera Hospital-Based Intervention for 7 Days (CHoBI7) NCT06498817 | Johns Hopkins Bloomberg School of Public Health | N/A |
| Completed | Simulation Based Training In Medical Students NCT06929312 | CMH Lahore Medical College and Institute of Dentistry | N/A |
| Completed | Assessment of a Novel Fixed-dose Combination (FDC) Drug VR-AD-1005 for the Treatment of Acute Watery Diarrhea NCT06193408 | Hunazine Biotech S.L. | Phase 2 |
| Completed | Immune Response Elicited by Concomitant Administration of Oral Typhoid Fever (Vivotif®) and Cholera (Dukoral®) NCT06104345 | Helsinki University Central Hospital | Phase 4 |
| Recruiting | Cholera-Hospital-Based-Intervention-for-7-Days (CHoBI7) Water, Sanitation, and Hygiene (WASH) Case Area Target NCT06003816 | Johns Hopkins Bloomberg School of Public Health | N/A |
| Unknown | Co-administration Study of OCV, TCV and MR NCT05771779 | International Centre for Diarrhoeal Disease Research, Bangladesh | Phase 3 |
| Completed | Next Generation ORS: Comparing ORS With Calcium vs Standard ORS in Reducing Severity of Acute Watery Diarrhea NCT05814042 | University of Florida | Phase 2 / Phase 3 |
| Unknown | To Evaluate Safety of Oral Cholera Vaccine Hillchol® (BBV131) NCT05732766 | Bharat Biotech International Limited | Phase 3 |
| Unknown | First in Human Phase 1 Ascending Dose Study of PanChol in Healthy Volunteers NCT05657782 | Brigham and Women's Hospital | Phase 1 |
| Unknown | Immune Response to a Delayed Second Dose of Oral Cholera Vaccine NCT05453253 | Epicentre | Phase 4 |
| Unknown | A Phase III Randomized, Modified Double-blind, Multi-centric, Comparative Study, to Evaluate the Non-inferiori NCT05507229 | Bharat Biotech International Limited | Phase 3 |
| Recruiting | Preventative Intervention for Cholera for 7 Days NCT05166850 | Johns Hopkins Bloomberg School of Public Health | N/A |
| Active Not Recruiting | Single Dose Azithromycin to Prevent Cholera in Children NCT04326478 | Massachusetts General Hospital | Phase 2 |
| Completed | Immune Non-Inferiority, Safety and Lot-to-Lot Consistency of Oral Cholera Vaccine-Simplified Compared to Shanc NCT04760236 | International Vaccine Institute | Phase 3 |
| Completed | Impact Study of Cholera Vaccination in Endemic Areas - Seroprevalence NCT05829772 | Epicentre | — |
| Recruiting | Impact Study of Cholera Vaccination in Endemic Areas - Clinical Surveillance NCT04853186 | Epicentre | — |
| Completed | Water, Sanitation, and Hygiene Mobile Health Messages as an Innovative Tool to Facilitate Behavior Change NCT04816552 | Johns Hopkins Bloomberg School of Public Health | N/A |
| Completed | Cholera Anti-Secretory Treatment Trial NCT04150250 | PATH | Phase 2 |
| Completed | Effect of Extended Dose Intervals on the Immune Response to Oral Cholera Vaccine NCT03373669 | Johns Hopkins Bloomberg School of Public Health | Phase 4 |
| Completed | Immunogenicity of Cholera Vaccine in Children With IBD NCT03998449 | Medical University of Warsaw | N/A |
| Completed | Immunologic Responses to a Live Attenuated Oral Cholera Vaccine NCT03251495 | Emory University | Phase 2 |
| Completed | Cholera-Hospital-Based-Intervention-for-7-days NCT04008134 | Johns Hopkins Bloomberg School of Public Health | N/A |
| Completed | Impact Evaluation of Urban Water Supply Improvements on Cholera and Other Diarrhoeal Diseases in Uvira, Democr NCT02928341 | London School of Hygiene and Tropical Medicine | N/A |
| Completed | Safety and Immunogenicity of Locally Manufactured New (HL-OCV) Oral Cholera Vaccine NCT02823899 | International Centre for Diarrhoeal Disease Research, Bangladesh | Phase 1 / Phase 2 |
| Completed | Safety and Immunogenicity of Locally Manufactured Oral Cholera Vaccine NCT02742558 | International Centre for Diarrhoeal Disease Research, Bangladesh | Phase 2 |
| Unknown | Safety and Immunogenicity of a New Formulation of Euvichol® NCT02502331 | International Vaccine Institute | Phase 3 |
| Completed | Cholera Vaccine Investment Strategy in Bangladesh NCT02727855 | International Centre for Diarrhoeal Disease Research, Bangladesh | — |
| Unknown | Safety and Immunogenicity of a Killed Oral Cholera Vaccine in Infants NCT00548054 | International Vaccine Institute | Phase 2 |
| Terminated | Follow-up of Pregnant Women After a Mass Vaccination of Oral Cholera Vaccine (ShancholTM) in Nsanje Malawi NCT02499172 | Johns Hopkins Bloomberg School of Public Health | N/A |
| Completed | A Study of Two Doses of Oral Cholera Vaccine (Shanchol™) in Subjects Aged 1 Year and Older in Dominican Republ NCT02434822 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | PXVX0200 (CVD103-HgR) vs Shanchol in Mali NCT02145377 | University of Maryland, Baltimore | Phase 2 |
| Completed | A Study of Live Oral Cholera Vaccine, PXVX200 in Healthy Older Adults NCT02100631 | Bavarian Nordic | Phase 3 |
| Completed | A Phase 3 Lot to Lot Consistency Study of Live Oral Cholera Vaccine, PXVX0200 in Healthy Adults NCT02094586 | Bavarian Nordic | Phase 3 |
| Completed | A Study of Two Doses of Oral Cholera Vaccine (Shanchol™) in Subjects Aged 1 Year and Older in the Philippines NCT01949675 | Sanofi Pasteur, a Sanofi Company | Phase 4 |
| Completed | Safety and Efficacy Challenge Study of Live Oral Cholera Vaccine Candidate,PXVX0200, to Prevent Cholera NCT01895855 | Bavarian Nordic | Phase 3 |
| Completed | PK Study of iOWH032 in Adult Male/Female Healthy Volunteers & Adult Males With Cholera NCT01823939 | PATH | Phase 1 |
| Unknown | Effectiveness of a Bivalent Killed Whole Cell Based Oral Cholera Vaccine NCT01508507 | International Vaccine Institute | — |
| Completed | Single Dose Oral Cholera Vaccine Study in Dhaka, Bangladesh NCT02027207 | International Centre for Diarrhoeal Disease Research, Bangladesh | Phase 3 |
| Completed | Evaluation of a Boosting Regimen With Oral Cholera Vaccine NCT01579448 | Sachin Desai | Phase 4 |
| Completed | Bridging Study for Killed Oral Cholera Vaccine in Ethiopia NCT01524640 | International Vaccine Institute | Phase 4 |
| Completed | Evaluation of a Pilot Program to Introduce Cholera Vaccine in Haiti as Part of Global Cholera Control Efforts NCT02864433 | Brigham and Women's Hospital | — |
| Completed | Oral Cholera Vaccine Delivery in Rural Bangladesh NCT01811771 | International Centre for Diarrhoeal Disease Research, Bangladesh | N/A |
| Completed | Safety and Immunogenicity of the Live Oral Cholera Vaccine Candidate PXVX0200 NCT01585181 | Bavarian Nordic | Phase 1 |
| Completed | Pilot Introduction of Oral Cholera Vaccine in Orissa, India NCT01365442 | International Vaccine Institute | — |
| Completed | Study of Alternative Vaccination Schedule of Oral Cholera Vaccine NCT01233362 | International Vaccine Institute | Phase 2 |
| Completed | Safety and Immunogenicity of Single Dose Choleragarde® in HIV-Seropositive Adults NCT00741637 | International Vaccine Institute | Phase 2 |
| Completed | Introduction of Cholera Vaccine in Bangladesh NCT01339845 | International Centre for Diarrhoeal Disease Research, Bangladesh | N/A |
| Completed | Mass Oral Cholera Vaccination in Zanzibar NCT00709410 | International Vaccine Institute | N/A |
| Terminated | Safety and Immunogenicity of Peru-15 Vaccine When Given With Measles Vaccine in Healthy Indian and Bangladeshi NCT00624975 | International Vaccine Institute | Phase 2 |
| Completed | Protective Immunity to Human Cholera in Bangladesh NCT00349999 | National Institute of Allergy and Infectious Diseases (NIAID) | — |
| Completed | Studies of Immune Responses to Orally Administered Vaccines in Developing Country NCT01019083 | International Centre for Diarrhoeal Disease Research, Bangladesh | Phase 1 / Phase 2 |
| Completed | Ciprofloxacin Multiple Dose for Adult Cholera NCT00741052 | International Centre for Diarrhoeal Disease Research, Bangladesh | Phase 3 |
| Completed | Immunogenicity of One Versus Two Doses of Killed Oral Cholera Vaccine NCT00419133 | International Vaccine Institute | Phase 2 |
| Completed | Immunity to Human Cholera in Bangladesh NCT00401934 | National Institute of Allergy and Infectious Diseases (NIAID) | — |
| Completed | Randomized Controlled Trial of Killed Oral Cholera Vaccine in Kolkata NCT00289224 | International Vaccine Institute | Phase 3 |
| Completed | Effect of Probiotic on Immunogenicity of Oral Cholera Vaccine NCT00464867 | International Centre for Diarrhoeal Disease Research, Bangladesh | N/A |
| Completed | Safety and Immunogenicity of Oral Cholera Vaccine in Kolkata NCT00119197 | International Vaccine Institute | Phase 2 |
| Completed | Safety and Immunogenicity of a New Formulation of a Bivalent Killed, Whole-Cell Oral Cholera Vaccine NCT00128011 | International Vaccine Institute | Phase 2 |
| Completed | Efficacy of Benefiber-Added, Reduced-Osmolarity WHO-ORS in the Treatment of Cholera in Adults NCT00672308 | International Centre for Diarrhoeal Disease Research, Bangladesh | Phase 2 |
| Completed | Single Dose Azithromycin in the Treatment of Adult Cholera NCT00229944 | International Centre for Diarrhoeal Disease Research, Bangladesh | Phase 3 |
| Completed | Single Dose Ciprofloxacin in the Treatment of Childhood Cholera:Randomized Controlled Clinical Trial NCT00142272 | International Centre for Diarrhoeal Disease Research, Bangladesh | Phase 3 |
| Completed | Zinc Supplementation in Cholera Patients NCT00226616 | International Centre for Diarrhoeal Disease Research, Bangladesh | Phase 3 |